Trial of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma
Status:
Unknown status
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy and safety of cisplatin (CDDP) and
epirubicin (EPI) in the treatment of transcatheter chemoembolization for Hepatocellular
Carcinoma (HCC).